



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boldogh et al. ) Group Art Unit: 1617  
Serial No.: 10/691,330 ) Examiner: Unassigned  
Confirmation No.: 1384 ) Docket No. 265.00390101  
Filed: October 22, 2003 )  
For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF  
AS INHIBITORS OF APOPTOSIS AND OTHER CELLULAR DAMAGE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):


- ☒ **Small entity status is entitled to be asserted in the above-identified application.**  
☒ An itemized return postcard.  
☐ A Petition for Extension of Time for \_\_ month(s) and a check in the amount of \$\_\_ for the required fee.  
☒ A Supplemental Information Disclosure Statement (2 pgs); copies of 2 applications; 1449 forms (1pg); and copies of 1 document cited on the 1449 forms.  
☐ A check in the amount of \$\_\_, representing \_\_\_\_.  
☐ A certified copy of a \_\_ application, Serial No. \_\_, filed \_\_\_\_, the right of priority of which is claimed under 35 U.S.C. §119.  
☐ Other: \_\_\_\_.  
☐ Amendment \_\_\_\_ No Additional fee is required. \_\_\_\_ The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$9 =	
Independent Claims				x \$43 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$145 Here →					
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

**CERTIFICATE UNDER 37 C.F.R. §1.8:** The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 1 day of March, 2004.

MUETING, RAASCH & GEBHARDT, P.A.  
Customer Number: 26813

By:   
Name: Ann M. Mueeting  
Reg. No.: 33,977  
Direct Dial: 612-305-1217  
Facsimile: 612-305-1228



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Boldogh et al. ) Group Art Unit: 1617  
Serial No.: 10/691,330 ) Examiner: Unassigned  
Confirmation No.: 1384 ) Docket No. 265.00390101  
Filed: October 22, 2003 )  
For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF  
AS INHIBITORS OF APOPTOSIS AND OTHER CELLULAR DAMAGE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):


- ☒ **Small entity status is entitled to be asserted in the above-identified application.**  
☒ An itemized return postcard.  
☐ A Petition for Extension of Time for \_\_ month(s) and a check in the amount of \$\_\_ for the required fee.  
☒ A Supplemental Information Disclosure Statement (2 pgs); copies of 2 applications; 1449 forms (1pg); and copies of 1 document cited on the 1449 forms.  
☐ A check in the amount of \$\_\_, representing \_\_\_\_.  
☐ A certified copy of a \_\_ application, Serial No. \_\_, filed \_\_\_\_\_, the right of priority of which is claimed under 35 U.S.C. §119.  
☐ Other: \_\_\_\_.  
☐ Amendment ☐ No Additional fee is required. ☐ The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$9 =	
Independent Claims				x \$43 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$145 Here →					
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

**CERTIFICATE UNDER 37 C.F.R. §1.8:** The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 1 day of March, 2004.

MUETING, RAASCH & GEBHARDT, P.A.  
Customer Number: 26813

By:   
Name: Ann M. Mueting  
Reg. No.: 33,977  
Direct Dial: 612-305-1217  
Facsimile: 612-305-1228



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boldogh et al. ) Group Art Unit: 1617  
Serial No.: 10/691,330 ) Examiner: Unassigned  
Confirmation No.: 1384 ) Docket No. 265.00390101  
Filed: October 22, 2003 )  
For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF  
AS INHIBITORS OF APOPTOSIS AND OTHER CELLULAR DAMAGE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):


- ☒ Small entity status is entitled to be asserted in the above-identified application.  
☒ An itemized return postcard.  
☐ A Petition for Extension of Time for \_\_ month(s) and a check in the amount of \$\_\_ for the required fee.  
☒ A Supplemental Information Disclosure Statement (2 pgs); copies of 2 applications; 1449 forms (1pg); and copies of 1 document cited on the 1449 forms.  
☐ A check in the amount of \$\_\_, representing \_\_\_\_.  
☐ A certified copy of a \_\_ application, Serial No. \_\_, filed \_\_\_\_\_, the right of priority of which is claimed under 35 U.S.C. §119.  
☐ Other: \_\_\_\_.  
☐ Amendment ☐ No Additional fee is required. ☐ The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$9 =	
Independent Claims				x \$43 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$145 Here →					
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

**CERTIFICATE UNDER 37 C.F.R. §1.8:** The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 1 day of March, 2004.

MUETING, RAASCH & GEBHARDT, P.A.  
Customer Number: 26813

By:   
Name: Ann M. Mueting  
Reg. No.: 33,977  
Direct Dial: 612-305-1217  
Facsimile: 612-305-1228



PATENT  
Docket No.265.00390101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Boldogh et al.	)	Group Art Unit: 1617
		)	
Serial No.:	10/691,330	)	Examiner: Unassigned
Confirmation No.:	1384	)	
		)	
Filed:	October 22, 2003	)	
		)	
For:	USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF AS INHIBITORS OF APOPTOSIS AND OTHER CELLULAR DAMAGE		


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. As this patent application was filed after June 30, 2003, copies of the U.S. patents and U.S. patent application publications listed on the attached 1449 form have not been submitted. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Applicants also wish to bring the Examiner's attention to the following pending U.S. Applications, as well as any documents, Office Actions that may include rejections of similar claims, and any provisional U.S. patent applications referenced in the pending U.S. applications or in their file wrappers. A copy of each of the below-listed pending U.S. Patent Applications is provided herewith.



Supplemental Information Disclosure Statement

Page 2 of 2

Applicant(s): Boldogh et al.

Serial No.: 10/691,330

Confirmation No.: 1384

Filed: October 22, 2003

For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF AS INHIBITORS OF APOPTOSIS AND OTHER CELLULAR DAMAGE

**List of Pending Non-Published U.S. Patent Applications**

Applicant(s)	Application Number	Filing Date	Serial No. of Provisional Application to which listed Application claims priority
Stanton et al.	09/641,801	08/17/00	60/149,311
Boldogh	09/641,802	08/17/00	60/149,633

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

Respectfully submitted for

**Boldogh et al.**

By  
Mueiting, Raasch & Gebhardt, P.A.  
P.O. Box 581415  
Minneapolis, MN 55458-1415  
Phone: (612)305-1220  
Facsimile: (612)305-1228  
Customer Number 26813


**CERTIFICATE UNDER 37 C.F.R. 1.8:**

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 1 day of March, 2004.

Name: Ann M. Mueiting

March 1, 2004  
Date

By: Ann M. Mueiting  
Ann M. Mueiting  
Reg. No. 33,977  
Direct Dial (612)305-1217

<b>INFORMATION DISCLOSURE STATEMENT</b> 	Atty. Docket No.: 265.00390101	Serial No.: 10/691,330
	Applicant(s): Boldogh et al.	Confirmation No.: 1384
	Application Filing Date: October 22, 2003	Group: 1617
	Information Disclosure Statement mailed: March <u>  </u> , 2004	

## U.S. PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		6,040,180	03/21/00	Johe			

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

## OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
	X	Gage et al., "Isolation, Characterization, and use of Stem Cells from the CNS," <i>Annu. Rev. Neurosci</i> , 1995;18: 159-92

EXAMINER	Date Considered
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	